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abstract
Cryptococcus  infection in HIV / AIDS patients results in cryptococcal meningitis, a major cause of subacute meningitis  with 
100% mortality if not receiving appropriate antifungal therapy. An examination of cryptococcal antigen will provide risk information 
for patients who will experience cryptococcal meningitis. Better diagnosis in asymptomatic and symptomatic phases of cryptococcosis 
are key components to reduce morbidity and mortality. This study aims to determine the proportion of cryptococcal antigenemia 
in HIV / AIDS patients treated at Intermediate Treatment-Infectious Diseases Unit of Dr. Soetomo General Hospital Surabaya. 
Cryptococcal antigenemia was examined in HIV / AIDS patients with suspected Cryptococcus infection and CD4+ T cell lymphocyte 
count <200 cell /μl. The examination used a lateral flow assay diagnostic tool, a simple FDA(Food and Drug Administration)-approved 
immunochromatographic test system for detection of capsular polysccharide antigens of Cryptococcus species complex (Cryptococcus 
neoformans and Cryptococcus gattii) in blood. This test meets all of the World Health Organization ASSURED criteria (affordable, 
sensitive, specific, user friendly, rapid/robust, equipment-free, and delivered). Sensitivity and specifiticy of this method from serum are 
both 100%. There were 3 positive cryptococcal antigenemia from 41 serum HIV / AIDS patients with suspected cryptococcus infection 
at Intermediate Treatment- Infectious Diseases Unit of Dr. Soetomo General Hospital Surabaya. All of these patients were male aged 
over 36 years, had CD4+ T cell lymphocytes <100 cell /μl and had never received antiretroviral therapy before. The proportion of 
cryptococcal antigenemia in HIV / AIDS patients with suspected Cryptococcus infection at Intermediate Treatment-Infectious Diseases 
Unit of Dr. Soetomo General Hospital Surabaya was 7.32%. 
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abstrak
Infeksi jamur Cryptococcus pada pasien HIV/AIDS mengakibatkan cryptococcal meningitis, yang merupakan penyebab utama 
meningitis subakut dengan mortalitas sebesar 100% bila tidak mendapatkan terapi antijamur yang tepat. Pemeriksaan antigen 
cryptococcal akan memberikan informasi risiko pasien yang akan mengalami cryptococcal meningitis. Semakin baik dan cepat diagnosis 
Cryptococcus antigenemia baik dilakukan pada fase simptomatik maupun asimptomatik cryptococcosis merupakan kunci penting dalam 
mengurangi morbiditas dan mortalitas. Penelitian ini bertujuan mengetahui proporsi cryptococcal antigenemia pada pasien HIV/AIDS 
yang dirawat di Unit Perawatan Intermediate Penyakit Infeksi Rumah Sakit Dr. Soetomo Surabaya. Dilakukan pemeriksaan cryptococcal 
antigenemia pada pasien HIV/AIDS dengan kecurigaan infeksi Cryptococcus dan hitung limfosit T CD4+<200sel/μl. Pemeriksaan 
menggunakan alat diagnostik lateral flow assay yang merupakan teknik imunokromatografi yang telah disetujui oleh FDA (Food and 
Drug Administration) dan dapat mendeteksi antigen kapsul polisakarida dari kompleks spesies cryptococcus (Cryptococcus neoformans 
dan Cryptococcus gattii) dari darah. Pemeriksaan ini memenuhi kriteria dari WHO (World Health Organization) antara lain mudah 
dijangkau, sensitif, spesifik, mudah digunakan, cepat, tidak memerlukan peralatan yang sulit didapat, dan mudah dibawa. Sensitifitas 
dan spesifisitas pemeriksaan ini dari serum adalah sebesar 100%. Didapatkan hasil penelitian yaitu 3 positif cryptococcal antigenemia 
dari 41 serum pasien HIV/AIDS dengan kecurigaan infeksi cryptococcus di Unit Perawatan Intermediate Penyakit Infeksi Rumah Sakit 
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Dr. Soetomo Surabaya. Semua pasien tersebut adalah laki-laki, berusia diatas 36 tahun , memiliki hitung limfosit T CD4+<100 sel/μl 
dan belum pernah mendapat terapi ARV sebelumnya. Proporsi cryptococcal antigenemia pada pasien HIV/AIDS dengan kecurigaan 
infeksi Cryptococcus di Unit Perawatan Intermediate Penyakit Infeksi Rumah Sakit Dr. Soetomo Surabaya adalah sebesar 7.32%. 
Kata kunci: cryptococcal antigenemia, AIDS, HIV, RSUD Dr. Soetomo, Surabaya
introduction
HIV/AIDS has been a cause of death for mostly 
humans in their productive times. Death is mainly due 
to opportunistic infection. Opportunistic infection is an 
immune system will not cause illness but is fatal in people 
with decreased immunity, as in HIV/AIDS patients.1
Cryptococcal meningitis is a major cause of subacute 
meningitis and death in patients with advanced HIV 
infection, affecting an estimated one million people each 
year, especially in sub Saharan Africa.2,3
Cryptococcal antigenemia testing will provide risk 
information for patients who will experience cryptococcal 
meningitis and death. Therefore, appropriate antifungal 
administration in patients with positive cryptococcal 
antigenemia (CrAg) is highly recommended. Rapid 
diagnostic testing using LFA (lateral flow immunoassay) 
method recommended by WHO is also recommended as 
a screening diagnostic method especially in HIV/AIDS 
patients with mild symptoms (no neurological disorders) 
or asympomatic. LFA examination is inexpensive and easy 
to perform, giving a sensitivity and specificity of more than 
95% within 10 minutes.4
More than 80% positive CrAg was obtained in HIV/
AIDS patients with CD4+ T cell lymphocyte count <100 
cells/µl. In other African and American studies, it was also 
found in HIV/AIDS patients with CD4+ T cell lymphocyte 
count between 100-200 cells/µl.5,6
This study aim to determine the proportion of 
Cryptococcal antigenemia in HIV/AIDS patients treated 
at Dr. Soetomo Hospital Surabaya.
material and method
study Design and patients
This was an observational study with cross sectional 
study design to study the proportion of Cryptococcal 
antigenemia.  HIV/AIDS patients ≥21 years old confirmed 
by three methods of HIV examination, CD4+ count <200 
cells/µl with suspected cryptococcal antigenemia (had 
fever with or without headache) were enrolled. Study 
participants were not required to be ART naive. Patients 
treated for cryptococcal infection in the last three months 
or currently taking an antifungal agent were excluded from 
study participation. 
Ethics statement 
The study was conducted according to the principles 
of the Declaration of Helsinki. Written informed consent 
was required from all study participants and the study was 
approved by Ethical Committee of Dr. Soetomo Hospital, 
Surabaya, Indonesia (No. 382/Panke.KKE/V/2017). 
procedures
A blood sample was obtained from each study 
participant to perform cryptococcal antigen Lateral 
Flow Assay (IMMY, USA), a simple FDA-approved 
immunochromatographic test system for detection of 
capsular polysaccharide antigens of Cryptococcus species 
complex (Cryptococcus neoformans and Cryptococcus 
gattii) in blood. Serum was separated from the blood sample. 
According to IMMY manufacturer’s recommendation one 
drop of lateral flow specimen was added to microtube, and 
then 40µl of serum was added to microtube. After that, 
lateral strip was immersed to the mixture and stayed for 10 
minutes. The test is positive if there were 2 line on strip, 
negative test if only 1 line on strip. Step by step of IMMY 
CrAg LFA can be seen in Figure 1. 
Data Analysis
figure 1. Step by step of IMMY CrAg LFA.7
All analyses were performed using SPSS 16. Chi square 
was used to determine factors associated with positive 
cryptococcal antigenemia. A p value ≤0.05 was considered 
significant. 
result and discussion
The diagnostic use for detection of cryptococcal 
capsular polysacchride antigen (CrAg) in serum by 
latex agglutination test (CrAg-latex) or enzym-linked 
immunoassay (EIA) has been available for over decades. 
Better diagnostics in asymptomatic and symptomatic 
phases of cryptococcosis are key components to reduce 
mortality.8
Cryptococcal antigen lateral flow assay (CrAg LFA) 
was included in the armamentarium for diagnosis. 
Unlike the other tests, the CrAg LFA is a dipstick 
immunochromatographic assay, in a format similar to 
the home pregnancy test, and requires little or no lab 
infrastructure. This test meets all of the World Health 
Organization ASSURED criteria (affordable, sensitive, 
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specific, user friendly, rapid/robust, equipment-free, and 
delivered).8
CrAg LFA has better analytical sensitivity for 
Cryptococcus gattii than CrAg-latex or EIA. Sensitivity and 
specificity of CrAg LFA from serum are both 100%.7
A total of 41 HIV/AIDS patients were enrolled into the 
study. The mean age of those enrolled was 36.37 years and 
90.24% were male. The prevalence of male against female 
can be explained by the higher incidence of HIV in men. 
The prevalence of cryptococcal antigenemia in 
Soetomo Hospital is 7.32%. The mean global prevalence 
of cryptococcal antigenemia is 6%.4 Positive CrAg 
LFA were 3 males from 41 patient. A 3% prevalence of 
cryptococcal antigenemia is the point at which the cost of 
treating cryptococcal meningitis with amphotericin B is 
greater than the cost of screening for CrAg examination. 
In Uganda, screening to prevent a case of cryptococcal 
meningitis requires a cost of $28, whereas to prevent a 
single death due to cryptococcal meningitis costs $40.9 The 
gold standard treatment for cryptococcal meningitis is to 
use amphotericin B which are known to be expensive and 
difficult to obtain especially by low-income countries, so 
more often  fluconazole is used.10 Other analyses reported 
that CrAg screening in areas with prevalence of <1% 
remained “cost-effective” due to lower LFA screening costs 
when compared with CrAg latex.9,11
The host gender also plays a role in the pathogenesis 
of cryptococcal, which estrogen can inhibit the growth of 
cryptococcus in vitro. Male immune responses are less 
efficient in controlling cryptococcus infections, because 
male macrophages tend to be killed by cryptococcus rather 
than phagocytosis of cryptococcus.12,13 In this study there 
is no correlation between male and female with positivity 
of cryptococcal antigenemia (p:1.0). There is also no 
correlation between male and female with positivity of 
cryptococcal antigenemia in another studies.
All of the positive patients are >36 years old, but there is 
no correlation between age with positivity of cryptococcal 
antigenemia (p:0.091) in this study. It is the same with 
another studies.7,11 One patient is 42 years old, another 
54 years old and 71 years old. Old patient (71 years old) 
was died, but the others were alive. The prognosis of 
cryptococcosis occuring in patients >60 years is generally 
worse.14 Baseline characteristics of patients according to 
cryptococcal antigenemia status can be observed in Table 
1. The positive test of cryptococcal antigen lateral flow 
assay can be seen in Figure 2.
There were 15 patients (36.6%) that already take ARV, 
96% from that have CD4+ T cells lymphocyte count <100 
cells/µl. In this study, all of CrAg positive patients were 
naive ARV, but there is no significant correlation (p:0.287), 
the same as studies that have already done by Vidal and 
Manga.6,12
There is no correlation within symptoms and CrAg 
positive antigenemia in this study (p:0.143 for fever, and 
p:0.539 for headache). In Manga’s study, fever present in 
82.5% of cases, was more frequent in patients with positive 
Table 1.  Baseline characteristics of patients according to 
cryptococcal antigenemia status.
parameter crAg-
positive
crAg-
negative
p
Age (years)
<36
>36
0
3
22
16
0.091
Sex
Male
Female
3
0
34
4
1.000
Fever
Yes
No
2
1
37
1
0.143
Headache
Yes
No
3
0
25
13
0.539
CD4+ cells
<100 cells/µl
>100 cells/µl
3
0
36
2
1.000
ARV
Yes
No
0
3
15
23
0.287
figure 2.  Positive test of Cryptococcal antigen lateral flow 
assay
antigenemia, but also have no significant corellation,7 but 
presenting headaches has significantly associated with 
positive cryptococcal antigenemia (p:0.000008).12
From total patients enrolled in this study, 95% have 
CD4+ T cell lymphocyte count <100 cells/µl, mean CD4+ 
T cell lymphocyte count is 31.5 cels/µl. CrAg positive 
patients in this study have CD4+ T cell lymphocyte count 
<100 cells/µl. But there is no significant correlation between 
CD4+ T cell lymphocyte count with positivity of CrAg LFA. 
Research conducted by Manga, Alemu and Ganiem also 
get the value of p>0.05.5,12,13
More opportunistic infections will occur in HIV/AIDS 
patients that have CD4+ lymphocyte count <100 cells/µl. 
The prevalence of opportunistic infections varies between 
regions.15 Opportunistic infections encountered in this study 
include pulmonary tuberculosis, cerebral toxoplasmosis, 
oropharyngeal candidiasis, PCP. The most common types 
of opportunistic infections in this study are pulmonary 
tuberculosis. Research conducted by Andama16 and 
Jarvis17states that tuberculosis is an infection that is often 
encountered in conjunction with cryptococcus antigenemia. 
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Indonesia, China and India are known to be a country with 
high tuberculosis burden.18
Several studies suggest that tuberculosis alone may 
result in a decrease in cellular immune function (a decrease 
in CD4+ T cell lymphocyte count), and that concurrent 
tuberculosis infection with HIV will result in significantly 
lower CD4+ T cell lymphocyte count compared to HIV 
monoinfection or Tuberculosis monoinfection.19–21
Our study is subject to several limitations. These include 
absence of lumbar punctures, which would help define 
the proportion of patients with cryptococcal meningitis 
among those with a positive cryptococcal antigen test, and 
no long-term clinical follow up of our patient cohort, also 
the high difference between CD4+<100 cells/µl and CD4+ 
100-200 cells/µl.
conclusion
The prevalence of Cryptococcal antigenemia in 
Soetomo Hospital’s  HIV/AIDS patients is 7.32%.  It means 
that CrAg screening in Soetomo Hospital will be “cost-
effective”. Future studies should be conducted to optimize 
screening and pre-emptive treatment of cryptococcosis. 
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